The Emergency Support Instrument provides support to help Member States in their efforts to address the coronavirus pandemic. It provides a broad EU toolbox to respond to needs which can be best addressed in a strategic, coordinated manner at European level. As a financing arm of the Joint European Roadmap towards lifting COVID-19 containment measures, the instrument helps mitigate the immediate consequences of the pandemic and anticipate the needs related to the exit and recovery.

The Emergency Support Instrument is based on the principle of solidarity and pools efforts and resources to quickly address shared strategic needs

All the latest information on the actions financed by the Emergency Support Instrument and their implementation will be published on this page.


A significant part of the budget available under the European Support Instrument will be used to secure the production of vaccines in the EU and sufficient supplies for its Member States through Advance Purchase Agreements with vaccine producers. Exploratory talks have been concluded with Sanofi on a contractual framework for the purchase of 300 million doses, and with Johnson and Johnson for an initial purchase of 200 million doses and the possibility to purchase 200 million more, on behalf of all EU Member States. The Commission continues intensive discussions with other vaccine manufacturers. For more on the Commission Coronavirus vaccines strategy, please visit the dedicated webpage.


On 28 July, the European Commission signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand name for the therapeutic drug Remdesivir. Veklury was the first medicine authorised at the EU level to treat COVID-19. With the support of the Commission, batches of Veklury will be made available to Member States and the UK as of early August and onwards. The Commission’s Emergency Support Instrument will finance the €63 million contract to ensure the treatment of approximately 30,000 patients with severe COVID-19 symptoms.  The Commission is now also preparing a joint procurement for further supplies of the medicine, expected to cover additional needs and supplies as from October onwards. 

On 31 July, the European Commission invited more than 200 blood-collection services from around the EU to apply for funding for the purchase of plasmapheresis equipment - equipment that collects plasma from recovered COVID-19 patients who are willing to donate. The additional equipment will increase the capacity to collect convalescent plasma and to build preparedness for the rapid collection in the event of future peaks or waves of the pandemic. With a budget of budget of €40 million, grants will be provided to public and non-governmental blood-collection services authorised to collect plasma. Learn more about treatments.

Transport of essential goods, medical teams and patients

ESI EU Member States can now apply to the European Commission for funding via the Emergency Support Instrument to transport essential goods, medical teams and patients affected by the coronavirus. This additional funding opportunity comes on top of support already available via the EU Civil Protection Mechanism and deliveries of protective equipment through rescEU.


Emergency kit the transport of medical items to where they are most needed, by financing the cargo transport of assistance and relief items to and between EU Member States
Protective equipment the transfer of patients between EU Member States or from Member States to neighbouring countries, so that where health services risk being overwhelmed, spare capacity elsewhere can be used, so ensuring treatment for as many patients as possible
Advisory group the transport of medical personnel and mobile medical teams between EU Member States and into the EU from other neighbouring countries, to help people wherever medical assistance is needed most

On 18 June, a pilot operation successfully delivered over seven tonnes of personal protective equipment to Bulgaria. The cargo includes over 500,000 protective masks, purchased by Bulgaria with transport costs covered by the EU.

The Commission has made available nearly €100 million for the procurement of essential health-related products, such as personal protective equipment (masks, gloves, glasses, gowns), ventilators and medicines for the prevention and treatment of COVID-19, as well as services to facilitate the quality and use of such products.

icon of a mask Personal protective equipment: the Commission has purchased 10 million masks to protect healthcare workers. These masks will be delivered in batches to the EU countries who expressed an interest.
Syiringe Treatments: the essential health related products facility has also been used to funded the purchase of treatment doses of Veklury, the brand name for the therapeutic Remdesivir (see above). Veklury was the first medicine authorised at the EU level to treat COVID-19.


EU medical and health support